Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection

AIDS

Volumn 25, Issue 18, 2011, Pages 2269-2278

  Haubrich, Richard H ^a   Riddler, Sharon A ^b   Ribaudo, Heather ^c   Direnzo, Gregory ^c,d   Klingman, Karin L ^e   Garren, Kevin W ^f   Butcher, David L ^g   Rooney, James F ^h   Havlir, Diane V ⁱ   Mellors, John W ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d STATE UNIVERSITY OF NEW YORK   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f ABBOTT LABORATORIES   (United States)

^g BRISTOL MYERS SQUIBB   (United States)

^h GILEAD SCIENCES   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antiretroviral therapy; nonnucleoside reverse transcriptase inhibitor; protease inhibitor; treatment outcome; viral dynamics

Indexed keywords

EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX; SEX DIFFERENCE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; BENZOXAZINES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LOPINAVIR; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; SEX FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 80855132700     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834d0c20     Document Type: Article

References (25)

1. Wu H, Lathey J, Ruan P, Douglas SD, Spector SA, Lindsey J, et al. Relationship of plasma HIV-1 RNA dynamics to baseline factors and virological responses to highly active antiretroviral therapy in adolescents (aged 12-22 years) infected through high-risk behavior. J Infect Dis 2004; 189:593-601. (Pubitemid 38270911)
2. Polis MA, Sidorov IA, Yoder C, Jankelevich S, Metcalf J, Mueller BU, et al. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. Lancet 2001; 358:1760-1765. (Pubitemid 33153000)
3. Ding AA, Wu H. Assessing antiviral potency of anti-HIV therapies in vivo by comparing viral decay rates in viral dynamic models. Biostatistics 2001; 2:13-29.
4. Ruane PJ, Richmond GJ, DeJesus E, Hill-Zabala CE, Danehower SC, Liao Q, et al. Pharmacodynamic effects of zidovudine 600mg once/day versus 300mg twice/day in therapy-naive patients infected with human immunodeficiency virus. Pharmacotherapy 2004; 24:307-312. (Pubitemid 38298755)
5. Louie M, Hogan C, Hurley A, Simon V, Chung C, Padte N, et al. Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. AIDS 2003; 17:1151-1156. (Pubitemid 36667757)
6. Kuritzkes DR, Ribaudo HJ, Squires KE, Koletar SL, Santana J, Riddler SA, et al. Plasma HIV-1 RNA dynamics in antiretroviralnaive subjects receiving either triple-nucleoside or efavirenzcontaining regimens: ACTG A5166s. J Infect Dis 2007; 195:1169-1176. (Pubitemid 46543448)
7. Molto J, Ruiz L, Valle M, Martinez-Picado J, Bonjoch A, Bravo I, et al. Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients. Antivir Ther 2006; 11:47-51.
8. Murray JM, Emery S, Kelleher AD, Law M, Chen J, Hazuda DJ, et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007; 21:2315-2321. (Pubitemid 350287458)
9. Wu H, Kuritzkes DR, McClernon DR, Kessler H, Connick E, Landay A, et al. Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points. J Infect Dis 1999; 179:799-807. (Pubitemid 29159324)
10. Wu H, Mellors J, Ruan P, McMahon D, Kelleher D, Lederman MM. Viral dynamics and their relations to baseline factors and longer term virologic responses in treatment-naive HIV-1-infected patients receiving abacavir in combination with HIV-1 protease inhibitors. J Acquir Immune Defic Syndr 2003; 33:557-563. (Pubitemid 36975842)
11. van Leth F, Huisamen CB, Badaro R, Vandercam B, de Wet J, Montaner JS, et al. Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: a 2NN substudy. J Acquir Immune Defic Syndr 2005; 38:296-300. (Pubitemid 40333494)
12. Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001; 344:720-725. (Pubitemid 32204989)
13. Farzadegan H, Hoover DR, Astemborski J, Lyles CM, Margolick JB, Markham RB, et al. Sex differences in HIV-1 viral load and progression to AIDS. Lancet 1998; 352:1510-1514. (Pubitemid 28512927)
14. Gallant JE, Rodriguez AE, Weinberg WG, Young B, Berger DS, Lim ML, et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005; 192:1921-1930. (Pubitemid 41681890)
15. Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009; 23:1109-1118.
16. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-2106. (Pubitemid 351679596)
17. Wu H. Statistical methods for HIV dynamic studies in AIDS clinical trials. Stat Methods Med Res 2005; 14:171-192. (Pubitemid 40467741)
18. Vaida F, Fitzgerald AP, Degruttola V. Efficient hybrid EM for linear and nonlinear mixed effects models with censored response. Comput Stat Data Anal 2007; 51:5718-5730. (Pubitemid 47125985)
19. Ding AA, Wu H. A comparison study of models and fitting procedures for biphasic viral dynamics in HIV-1 infected patients treated with antiviral therapies. Biometrics 2000; 56:293-300. (Pubitemid 30165122)
20. WuH, Ding AA. Population HIV-1 dynamics in vivo: applicable models and inferential tools for virological data from AIDS clinical trials. Biometrics 1999; 55:410-418. (Pubitemid 29302563)
21. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387:188-191. (Pubitemid 27209434)
22. Hlavacek WS, Stilianakis NI, Notermans DW, Danner SA, Perelson AS. Influence of follicular dendritic cells on decay of HIV during antiretroviral therapy. Proc Natl Acad Sci USA 2000; 97:10966-10971.
23. Arnaout RA, Nowak MA, Wodarz D. HIV-1 dynamics revisited: biphasic decay by cytotoxic T lymphocyte killing? Proc Biol Sci 2000; 267:1347-1354. (Pubitemid 30460003)
24. Flexner C. HIV-protease inhibitors. N Engl J Med 1998; 338:1281-1292. (Pubitemid 28216584)
25. Roberts NA, Martin JA, Kinchington D, Broadhurst AV, Craig JC, Duncan IB, et al. Rational design of peptide-based HIV proteinase inhibitors. Science 1990; 248:358-361.